Zhitong Finance App News, Renhe Pharmaceutical (000650.SZ) issued an announcement. The company's subsidiary Jiangxi Shanliang Pharmaceutical Co., Ltd. recently received the “Drug Registration Certificate” for sodium hyaluronate eye drops approved and issued by the State Drug Administration. According to reports, this drug is an eye drop with sodium hyaluronate as the main component. The clinical indications are: to relieve dry eye symptoms. Currently, several sodium hyaluronate eye drops are on the market in China.